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During the recent severe acute respiratory syndrome
(SARS) outbreak, the etiologic agent was identified as a
new coronavirus (CoV). We have isolated a SARS-associ-
ated CoV (SARS-CoV) strain by injecting Vero cells with a
sputum specimen from an Italian patient affected by a
severe pneumonia; the patient traveled from Vietnam to
Italy in March 2003. Ultrastructural analysis of infected Vero
cells showed the virions within cell vesicles and around the
cell membrane. The full-length viral genome sequence was
similar to those derived from the Hong-Kong Hotel M iso-
late. By using both real-time reverse transcription–poly-
merase chain reaction TaqMan assay and an infectivity
plaque assay, we determined that approximately 360 viral
genomes were required to generate a PFU. In addition,
heparin (100 mg/mL) inhibited infection of Vero cells by
50%. Overall, the molecular and biologic characteristics of
the strain HSR1 provide evidence that SARS-CoV forms a
fourth genetic coronavirus group with distinct genomic and
biologic features. 
A
n outbreak of atypical pneumonia, referred to as
severe acute respiratory syndrome (SARS), was iden-
tified in the Guangdong Province of People’s Republic of
China at the end of 2002 and spread to other Asian coun-
tries and Canada (1,2) from February through March 2003.
Individual cases (all in persons infected in Asia) were diag-
nosed in Europe during the same period (3). Anovel human
coronavirus (SARS-associated coronavirus [SARS-CoV])
has been isolated from the oropharyngeal specimens of
patients with SARS (4,5). Experimental infection of
macaques has confirmed that the SARS-CoV is the cause
of SARS (6,7). 
Coronaviruses are enveloped, positive-stranded RNA
viruses associated with enteric and respiratory diseases in
animals and humans; they are currently classified into
three antigenic groups: group 1 and 2 include mammalian
coronaviruses, and group 3 encompasses avian coron-
aviruses. Human coronaviruses are associated with com-
mon cold-like diseases and are included in both group 1
(CoV-229E) and 2 (CoV-OC43) (8). Sequence analysis of
the complete genome of SARS-CoV has shown an RNA
molecule of about 29,750 bases in length, with a genome
organization similar to that of other coronaviruses (9–11).
In spite of this similar organization, the SARS-CoV RNA
sequence is only distantly related to that of previously
characterized coronaviruses (9). Consequently, whether
the SARS-CoVhas “jumped” from a nonhuman host reser-
voir to humans and the molecular basis of such a jump
remain unanswered questions (12). Some biologic features
of the SARS-CoV described in vivo and in vitro differ
from those of other coronaviruses previously identified.
Among these features are the peculiar tropism of the virus
for Vero cells (a continuous cell line established from mon-
key kidney epithelial cells), its capacity for growth at 37°C
(while other respiratory coronaviruses grow at lower tem-
peratures), and its ability to infect lower respiratory tract
tissues (13). These aspects render the molecular and bio-
logic characterization of SARS-CoV important not only
for understanding the determinants of its pathogenic
potential but also for planning rational strategies of antivi-
ral therapy and vaccination. 
We have recently obtained a SARS-CoV isolate from a
frozen sputum sample collected from an Italian patient
affected by a respiratory disease of unknown cause; onset
of illness began during the patient’s travel to Vietnam in
March 2003. The viral strain has been designated as
SARS-CoV HSR1. To gain insight into SARS-CoV
biopathology, we analyzed the relevant features of SARS-
CoV HSR1 growth in vitro, including the ultrastructural
analysis of the consequences of virus replication in Vero
cells. We have optimized both a reverse transcription–
polymerase chain reaction (RT-PCR) TaqMan assay for
quantifying the number of viral genomes and a plaque
assay for performing titration of the virus infectivity. In
addition, we have completely sequenced the viral genome
of the SARS-CoV HSR1 and compared it to other SARS-
CoV strains recently isolated in disease-epidemic areas. 
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SARS-CoV Isolation
In March 2003, an Italian man who recently traveled
from Vietnam to Italy was affected by a respiratory disease
of unknown cause; he was hospitalized in a clinical unit for
acute infectious diseases in a public hospital in Milan,
Italy. A sputum sample was collected at the peak of illness
and stored at –80°C. Isolation of SARS-CoV was per-
formed with Vero cells maintained in Dulbecco’s modified
Eagle medium (D-MEM, BioWhittaker, Verviers,
Belgium) and supplemented with 10% fetal calf serum
(FCS, HyClone, Perbio Science Erembodegem-Aalst,
Belgium), penicillin/streptomycin (BioWhittaker), and 2.5
µg/mL Fungizone (Invitrogen Ltd, Life Technologies,
Paisley, UK) (complete medium). In detail, an aliquot (0.5
mL) of the sputum sample was mixed with 2 x 106 Vero
cell suspension in 2 mL of complete medium. After incu-
bation for 1 h at 37°C, 5% CO2, 4 mL of complete medi-
um was added, and the cell suspension was transferred into
a 25-cm2 tissue culture flask (Falcon, Becton Dickinson
Labware, Lincoln Park, NJ). Twenty-four hours after inoc-
ulation, the cell cultures were examined with an optical
microscope for evidence of cytopathic effects (CPE). An
aliquot of culture supernatant was collected and stored at
–80°C for RT-PCR evaluation. After an additional 24
hours, both the culture supernatant and the cells were col-
lected after 2 cycles of freeze thawing, followed by clarifi-
cation of the thawed contents by centrifugation at 1,000
x g and dispensation of the supernatant into aliquots stored
at –80°C (primary viral stock). For generation of the sec-
ondary and tertiary viral stocks, adherent Vero cells flasks
were seeded in a 25 cm2 tissue culture and injected with
0.5 mL of stored supernatant filtered with 0.45 µm filters.
Three days after infection, the cells and supernatant were
subjected to 2 cycles of freeze thawing, and the super-
natant was collected after centrifugation followed by filtra-
tion as described above (secondary viral stock). Finally,
Vero cells seeded in 2 flasks of 75 cm2 were injected with
1.5 mL of the second passage virus stock in a total volume
of 25 mL to generate a third-passage viral stock. 
RT-PCR Amplification of Viral Sequences
Direct SARS-CoV RNA amplification was performed
starting from the sputum sample treated with an equal vol-
ume of phosphate-buffered solution (PBS). RNAwas puri-
fied from 750 µL of the resulting homogenate by using the
Qiagen Viral RNA Mini Kit (Qiagen, Inc., Santa Clarita,
CA) (elution volume 50 µL), according to manufacturer’s
instructions. Viral RNA was extracted from 0.5 mL of cul-
ture supernatant with the same kit (elution volume 50 µL).
cDNA synthesis and subsequent amplification were per-
formed by using either nested RT-PCR or real-time RT-
PCR approach, as described elsewhere, with minor modi-
fications (3). In brief, 5 µL of extracted RNA was reverse-
transcribed for 30 min at 42°C by using Mo-MuLV RT, a
mixture of random hexamers, and an oligo-(dT) primer.
Two microliters of the synthesized cDNAwas subsequent-
ly amplified by using the following primers pairs: outer
primers: BNI-OUTS2, 5′-ATG AAT TAC CAA GTC AAT
GGTTAC-3′; BNI-OUTAS, 5′-CATAAC CAG TCG GTA
CAG CTA C-3′; inner primers: BNI-INS, 5′-GAA GCT
ATT CGT CAC GTT CG-3′; BNIINAS, 5′-CTG TAG
AAAATC CTAGCT GGAG-3′. Asequence of the SARS-
CoV RNA encompassing the target region was used as
positive control, and a sputum sample from a SARS-nega-
tive healthy donor and a feline coronavirus RNA extract
were used as negative controls. The amplified PCR prod-
uct was separated by agarose gel electrophoresis visual-
ized by ethidium bromide staining and sequenced directly
on an ABI PRISM 3100 Genetic Analyzer with ABI
PRISM BigDye Terminator v3.0 sequencing kit (Applied
Biosystems, Foster City, CA). SARS-CoV was then iden-
tified by searching for homologies between the amplified
fragment and previously deposited sequences using
BLAST. Finally, the quantitation of the viral RNAwas per-
formed in a TaqMan assay after generation of cDNA. The
primer pair and probe BNITMSARS1, 5′-TTATCACC-
CGCGAAGAAGCT-3′; BNITMSARAS2, 5′-CTC-
TAGTTGCATGACAGCCCTC-3′, BNI-TMSARP
6-carboxifluorescein-TCG TGC GTG GAT TGG CTT
TGATGT-6 carboxy-tetramethylrhodamin (3) were added
to the universal PCR master mix (Applied Biosystems) at
200 and 120 nM, respectively, in a final volume of 25 µL.
The standard was obtained by cloning the 77-bp fragment
into the pCR2.1 plasmid by using the TA cloning kit
(InVitrogen Corp., San Diego, CA). A linear distribution
(r = 0.99) was obtained between 101 to 108 copies.
SARS-CoV Plaque Infectivity Assay
To have the most effective quantitative assay of virus
infectivity and to compare the infectious titer with quanti-
tative molecular assays, we optimized a plaque assay
(determining the PFU/mL). Confluent Vero cells in 6 well
plates (Falcon) were incubated in duplicate with 1 mL of
PBS containing 100 µLof SARS-CoV HSR1 viral stock in
10-fold serial dilutions from –10e2 (1/100) to –10e8
(1/100,000,000). After 1 hour of incubation, the viral
inoculum was removed and 1 mL of 1% carboxymethyl-
cellulose (Sigma Chemical Corp., St. Louis, MO) overlay
with DMEM supplemented with 1% fetal calf serum was
added to each well. After 6 days of incubation, the cells
were stained with 1% crystal violet (Sigma) in 70%
methanol. The plaques were counted after being examined
with a stereoscopic microscope (SMZ-1500, Nikon). The
virus titer was calculated in PFU per milliliter.
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Adherent Vero cells were infected with 5 x 104 PFU/mL
of SARS-CoV HSR1 at the third passage in a T-75 flask.
Twenty-four hours after infection, Vero cells were
detached from the tissue culture flask with a cell scraper,
and the cell suspension was centrifuged at 173 x g for 4
min. The pellet was resuspended in PBS without Ca++ and
Mg++, and the suspension was spun at 173 x g for an addi-
tional 4 min. The cell pellet was resuspended and fixed in
4% formaldehyde and 2.5% glutaraldehyde in cacodylate
buffer and incubated for 5 min at room temperature. The
sample was then centrifuged at 13,414 x g for 5 min; the
pellet was fixed with 2% OsO4 in 2.5% glutaraldehyde in
cacodylate buffer for 60 min. The pellet was dehydrated in
graded ethanol, washed in propylene oxide and infiltrated
for 12 hours in a 1:1 mixture of propylene oxide and epox-
idic resin (Epon). Cells were then embedded in Epon and
polymerized for 24 hours at 60°C. Slides were cut with
ultramicrotome (Ultracut Uct, Leica, Deerfield, IL),
stained with uranyl acetate and lead citrate, and metaled.
The ultrathin sections of infected Vero cells were observed
through transmission electron microscopy (Hitachi
H7000). 
SARS-CoV HSR1 Genome RNA and 
Phylogenetic Reconstruction
Sequencing of the complete SARS-CoV HSR1 genome
was performed by using 68 partially overlapping primers
encompassing the whole viral genome. A 5′ rapid amplifi-
cation of PCR ends (RACE) technique was performed to
capture the 5′-untranslated region of the genome (10).
Each 750-bp fragment was gel-isolated by means of a
QIAQuick gel Extraction kit (Qiagen) and directly
sequenced from both directions inward and outward.
SeqScape version 2.0 (Applied Biosystems) software was
used for base calling, editing, and assembly of the frag-
ments. Manual check of the differences between the elec-
tropherograms and the reference sequence (Urbani isolate)
was performed and eventually led to reamplification or
resequencing of some fragments. The complete sequence
of SARS-CoV HSR1 strain was aligned with all the previ-
ously sequenced full-length genomes available from the
GenBank database by using ClustalW and editing with
BioEdit version 5.0.9 for manual corrections. Available
full-length sequences of SARS-CoV strains accessed from
GenBank and used for phylogenetic analysis and genotyp-
ing were as follows: Taiwan TC2 (AY338175), Taiwan
TC1 (AY338174), TWC (AY321118), Sin2774
(AY283798), Sin2748 (AY283797), Sin2679 (AY283796),
Sin2677 (AY283795), Sin2500 (AY283794), Frankfurt 1
(AY291315), BJ04 (AY279354), BJ03 (AY278490), BJ02
(AY278487), GZ01 (AY278489), CUHK-W1 (AY27
8554), ZJ01 (AY297028), TOR2 (AY274119), TW1 (AY
291451), CUHKSu10 (AY282752), BJ01 (AY278488),
Urbani (AY278741), and HKU-39849 (AY278491).
Sequences were trimmed to equivalent length and phylo-
genetic relationships were estimated with PAUP* (maxi-
mum-parsimony and maximum-likelihood methods by
using the p-distance model) and MEGA version 2.1. Trees
were edited by using Treeview. 
Results
Both nested RT-PCR and the real-time RT-PCR assays
performed on the sputum sample from a person with SARS
tested positive for SARS-CoV RNA. The viral load in the
sample was estimated to be 5.6 x 104 SARS-CoV RNA
copies/mL. Twenty-four hours after injection of Vero cells
with the sputum sample, a strong CPE was observed, as
indicated in Figure 1B. The CPE was diffused with cell
rounding with refractive appearance, and the cell monolay-
er was destroyed as compared to control uninfected Vero
cells (Figure 1A). The viral load in the culture supernatant
24 hours after injection with the clinical sample was 1.3 x
105 copies/mL as determined by quantitative real-time RT-
PCR. Serial passage of the virus on Vero cells to obtain a
tertiary viral stock yielded 9.1 x 108 copies/mL. A plaque
assay was optimized to determine the in vitro infectivity of
SARS-CoV. The tertiary viral stock tested 2.5 x 106
PFU/mL in the plaque assay, suggesting that about 360
genomes were required to generate a single plaque in tis-
sue cultures, at least under the conditions described here.
We also used the plaque assay for testing the potential
inhibitory effect on virus infectivity of a single concentra-
tion of heparin, the prototypic compound of a class of
inhibitors of virus entry for enveloped viruses including
HIV type 1 (HIV-1) (14) and herpes simplex virus 1 and 2
(HSV-1 and 2) (15). Heparin indeed reduced the formation
of plaques by 50% when added 30 min before infection of
Vero cells with 100 PFU/mL of the SARS-CoV (Figure 2). 
Thin-section electron microscopy showed the typical
features of intracellular CoV particles. Cells were engulfed
with viral particles localized in cytoplasmic vesicles
(Figure 3A). This feature is typical of all Coronaviridae
viruses that bud intracellularly at membranes of the inter-
mediate compartment between the endoplasmic reticulum
and the Golgi complex, whereas newly assembled virions
reach the cell surface by vesicular transport (16). After the
extracellular release, virus particles were found in large
clusters adjacent to the plasma membrane, as evidenced in
Figure 3B. Overall, the ultrastructural analysis document-
ed that SARS-CoV cultivated in Vero cells behaved like a
typical coronavirus, characterized by intracellular budding
(Figure 3, panels C and D). 
The sequence of SARS-CoV strain HSR1 genomic
RNA was 29,751 bases in length, with a polyA tail. We
identified the major open reading frames (ORFs), coding
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lope (E) matrix (M), nucleocapsid (N) gene products, and
at least other 10 proteins, including a few of unknown
function. The complete sequence of SARS-CoV strain
HSR1 has been deposited in the GenBank database
(GenBank accession no. AY323977). This sequence was
aligned with those of the other 21 SARS-CoV isolates to
facilitate phylogenetic analysis. Overall, the mean differ-
ence in nucleotide composition between all the isolates
was 18 ± 1 nt variations within the whole genomes, thus
confirming the genetic conservation observed previously
(9). On the whole, 149 sites were variable among the 22
aligned isolates, and 24 loci in the viral genome varied in
more than one isolate, including in the SARS-CoV HSR1
genome (recurrent mutations). Eleven of 24 recurrent
mutations were silent, whereas 3 of 13 mutations generat-
ing amino acid substitutions were observed within the N-
terminal domain of the spike glycoprotein gene (positions
21,722, 22,223, and 22,423, determining a G to D, an I to
T, and a G to R amino acid change, respectively). Six
mutations were detected in the replicase gene (positions
8,572, 9,404, 9,479, 9,854, 17,564, and 19,084, determin-
ing a V to L, a V to A, a V to A, an A to V, a D to E, and a
T to I amino acid change, respectively), and 1 mutation
was found in the matrix protein (position 26,600, deter-
mining an A to V amino acid change). The phylogenetic
analysis was also performed by using the maximum parsi-
mony method, considering only sequence variants that
recurred in more than one strain in order to reduce the
mutational noise caused by PCR or sequencing mistakes.
Figure 4 shows the phylogenetic tree obtained with the
maximum likelihood method. The maximum parsimony
trees produced the same structure with minor changes in
the subtrees’ branch patterns (data not shown). In these
analyses, SARS-CoV HSR1 appears to be strongly related
to strains isolated from patients who had traveled from
Hong Kong to different geographic areas (Singapore,
Canada, Vietnam) and spread the infection to their home
countries in a few cases. 
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Figure 1. Cytopathic effect (CPE) of primary severe acute respira-
tory syndrome–associated coronavirus strain HSR1 isolate. A,
uninfected Vero cells form a continuous monolayer of spindle-
shaped cells. B, a strong CPE was observed after 24 hours of
incubation of Vero cells with the patient sputum sample (primary
isolate).
Figure 2. Effect of the sulfated polysaccharide heparin (100
µg/mL) added 30 minutes before injecting Vero cells with 100
PFU/mL of severe acute respiratory syndrome–associated coron-
avirus strain HSR1. The results are expressed as number of
plaques/well and represent the mean ± SEM of two independent
experiments each carried out in duplicate cultures. The p value
was calculated by the Mann-Whitney U test. Discussion 
The isolation of a novel CoV in persons with SARS and
proof of its etiologic role in this disease underscore the
importance of identifying the pathogenic determinants of
SARS-CoV. This information may be central to plan spe-
cific therapeutic and preventive strategies against SARS.
Major areas of research include the following: 1) analyz-
ing growth characteristics of SARS-CoV in vitro; 2) eval-
uating virus-host relationships at the molecular level; 3)
understanding both SARS-CoV genome organization and
the role of nonstructural proteins of unknown function; 4)
studying the evolutionary relationships of different coron-
aviruses of animal and human origin; and 5) identifying
targets for anti-CoV chemotherapy and vaccination. In our
study, we characterized a novel isolate of SARS-CoV (des-
ignated HSR1 strain). The analysis of the complete
sequence of SARS-CoV HSR1 genome showed the same
organization in ORFs previously described in this novel
human virus (10) and confirmed the relative genetic stabil-
ity among the different isolates (9). However, for other
SARS-CoVs isolates, amino acid changes were observed
in this HSR1 strain at the level of the N-terminal domain
of the spike glycoprotein, the viral replicase, and the
matrix protein. Despite this relative stability, phylogenetic
analysis of the HSR1 isolate (Figure 4) has shown that the
virus is more related to the strains isolated in patients who
had traveled from Hong Kong to different geographic
areas, such as Singapore, Canada, and Vietnam, than to the
Beijing isolates. In addition, we have observed that other
biomolecular features shared by most Coronaviridae coex-
ist in SARS-CoV HSR1 with particular characteristics that
seem to be unique of the novel virus. In particular, SARS-
CoV is able to replicate in Vero cells with a rapid produc-
tion of high virus titers and fast CPE. By using quantitative
molecular and biologic assays, we could estimate that,
under our experimental conditions, 360 genomes are
approximately required to form a plaque of infectivity in
vitro. SARS-CoV seems unlike most of the other respira-
tory coronaviruses infecting humans, which fail to grow
efficiently in tissue cultures and are easily detectable by
using PCR amplification methods only (17). Infection in
Vero cells showed most of the usual characteristics of the
CoV replication (16), including intracellular budding of
virions, as demonstrated by electron microscopy. 
To investigate whether SARS-CoV could be inhibited
by polyanions, we tested the effects of the prototypic sul-
fated polysaccharide heparin (Figure 2) on in vitro infec-
tion. Incubation of Vero cells with heparin (100 µg/mL) 30
min before SARS-CoV injection curtailed infection by
50%. Polyanions have demonstrated antiviral activity (18)
against enveloped viruses such as HIV and HSV through
specific interaction with cells and after inhibition of virus
attachment and entry (14). Heparin, a prototypic polyan-
ion, inhibits attachment and entry of virus particles into
cell by impeding the interaction of the V3 region of gp120
with HIV specific chemokine coreceptor (19). In the case
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Figure 3. Ultrastructural analysis of Vero cells infected with severe
acute respiratory syndrome–associated coronavirus (SARS-CoV)
strain HSR1. A, intracellular budding of SARS-CoV in large vesi-
cles containing CoV virions (magnification x30,000); B, clusters of
extracellular virions adjacent to the plasma membrane (magnifica-
tion x50,000); C and D, intracellular budding of SARS-CoV virions
(magnification x50,000). 
Figure 4. Phylogenetic tree obtained by applying PAUP* (maxi-
mum-likelihood methods using the p-distance model) applied to
complete genome sequences of the severe acute respiratory syn-
drome–associated coronavirus (SARS-CoV) HSR1 strain and the
21 other SARS-CoV isolates. of HSV, heparin inhibits the interaction of some HSV
envelope glycoprotein to the heparan sulfate that mediates
viral attachment to the target cell surface (20,21). The par-
tial inhibition of SARS-CoV HSR1 by heparin suggests
that the envelope proteins coating the SARS-CoV virions
might be endowed with positively charged amino acids
that could interact with negatively charged sulfate groups
present on heparan sulfate proteoglycans expressed on the
surface of target cells. Vero cells, the target of both HSV
and dengue 4 (22) replication, replicate SARS-CoV more
efficiently than several other cell lines. 
In conclusion, our study characterized a novel SARS-
CoV isolate, which was to date the second isolate obtained
in Europe. The sequence analysis indicates that SARS-
CoV HSR1 clusters together with the Hong Kong,
Singapore, and Canada isolates. The coexistence of gener-
al coronavirus features with important biologic and molec-
ular specificity of SARS-CoV, together with the evidence
that SARS-CoV does not appear to be linked to any of the
other three genetic groups of known coronaviruses, strong-
ly suggests it represents a new, fourth genetic coronavirus
group, with distinct genomic and biologic features. In light
of this evidence, efforts to identify new types of animal
coronaviruses as well as to better understand the peculiar-
ities of SARS-CoV are important in addressing its possible
animal origin and in understanding the biology of
Coronaviridae and their evolutionary features. 
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